Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) by Mototsugu Shimokawa, Hiroshi Tanaka, Nobuyuki Yamamoto, Koichi Azuma, Hidetoshi Hayashi, Ryo Toyozawa, Kazumi Nishino, Kazuhiko Nakagawa, Isamu Okamoto, Hideo Saka, Takashi Seto, Kaname Nosaki, Shunichi Sugawara, Haruyasu Murakami, Terufumi Kato, Seiji Niho, Masahide Oki, Hiroshige Yoshioka, Haruko Daga, Rie Tohnai

Get full text